Opendata, web and dolomites


Discovery of breast cancer aggressiveness markers using topo-proteomics mapping

Total Cost €


EC-Contrib. €






Project "PROTEOMICAN" data sheet

The following table provides information about the project.


Organization address
address: RAMAT AVIV
city: TEL AVIV
postcode: 69978

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 1˙699˙261 €
 EC max contribution 1˙699˙260 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-STG
 Funding Scheme ERC-STG
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2021-06-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TEL AVIV UNIVERSITY IL (TEL AVIV) coordinator 1˙699˙260.00


 Project objective

'In the proposed research we will explore the functional proteomic diversity of histologically-defined regions within human breast tumors, aiming to identify novel protein biomarkers of tumor aggressiveness. Once identified, these proteins will serve as potent diagnostic markers and therapeutic targets. Towards this aim we will perform genome-scale proteomic profiling on tumor regions displaying diverse histopathology. This will be followed by functional investigation of these cancer cell sub-populations to determine their tumorigenic potential, and search for microparticle-based proteomic biomarkers from serum samples towards identification of cancer aggressiveness in blood tests. Analysis of the proteomic diversity holds a promise to reveal yet unidentified regulators of the tumorigenic phenotype as quantitative protein profiling is expected to most faithfully predict cellular phenotypes. This will be accomplished using the 'super-SILAC' technology, which I developed during my post-doctoral research. Using this technology, we identified over 12,000 proteins in formalin-fixed paraffin embedded breast cancer tumors. In the current project we will take one large step further, namely, microdissect and analyze selected regions in breast tumors based on local histopathological characteristics, such as the expression of known markers, cancer cell density, the vicinity to blood vessels and to the tumor invasive front. This 'topological map' of the proteome will be followed by functional in vitro and in vivo studies, directly probing the aggressiveness of these cell populations, manifested by an accelerated proliferation and invasive/metastatic capacity. Finally, proteins associated with tumor aggressiveness will serve as blood-based biomarkers for predicting the tumorigenic phenotype using non-invasive tests. This work will set the basis for quantitative probing of tumor heterogeneity, which is crucial for accurate diagnosis and effective therapy. '


year authors and title journal last update
List of publications.
2017 Mariya Mardamshina, Tamar Geiger
Next-Generation Proteomics and Its Application to Clinical Breast Cancer Research
published pages: 2175-2184, ISSN: 0002-9440, DOI: 10.1016/j.ajpath.2017.07.003
The American Journal of Pathology 187/10 2020-02-21

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROTEOMICAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROTEOMICAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


The Mass Politics of Disintegration

Read More  

InsideChromatin (2019)

Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin Domains

Read More  

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More